Os Therapies Requests Meeting With FDA to Gain Agreement on Surrogate Endpoint(S) for Breakthrough Therapy Designation & Accelerated Approval of Ost-Her2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.